Verve Therapeutics is a brand on a mission to protect the world from cardiovascular disease (CVD). Despite available treatments, CVD remains the leading cause of death worldwide, impacting hundreds of millions of people. In the United States alone, one person dies every 34 seconds from CVD, with around 800,000 heart attacks occurring each year.

To address this global challenge, Verve is pioneering the development of groundbreaking, single-course gene editing medicines. Leveraging advances in human genetics and gene editing, their approach aims to change the treatment paradigm for CVD. With a pipeline of in vivo gene editing programs that target genes in the liver contributing to CVD risk, Verve is working towards safely turning off these genes.

This innovative approach is being evaluated in the Phase 1b heart-1 clinical trial. Committed to improving the lives of those living with CVD, Verve collaborates with healthcare professionals, combining the expertise of a team specializing in cardiovascular medicine, genetics, gene editing, delivery technologies, and drug development. Verve Therapeutics strives to protect the world from cardiovascular disease through their innovative approach and expert team